Insider · CIK 0001688199
Simon Read
Files at DNTH (Dianthus Therapeutics, Inc. /DE/). First filing Aug 11, 2026, latest Aug 19, 2026.
In brief
Simon Read files SEC Form 4 as director at DNTH (Dianthus Therapeutics, Inc. /DE/). Since Aug 11, 2026, Simon Read has reported 0 open-market buys worth $0 and 2 open-market sells worth $631k, the latest filed on Aug 19, 2026.
A track record needs three past buys with six months of prices behind them; Simon Read has 0, so none is measured yet.
The newest scored trade: sold $327k of DNTH on Aug 19, 2026, filed Aug 19, 2026, scored 30 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $631k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Dianthus Therapeutics, Inc. /DE/ | $327k 2,778 shares | -100% | +401% from low-2% from high | |
| 29Weak | Dianthus Therapeutics, Inc. /DE/ | $304k 2,777 shares | -100% | +492% from low-1% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | 5,550 0.01% of outstanding | $624k | Aug 10, 2026 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +2,778 | $18.36 | $51k | 2,778 | Aug 19, 2026 |
| Aug 19, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -2,778 | $117.55 | $327k | 0 | Aug 19, 2026 |
| Aug 19, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,778 | $0.00 | $0 | 19,445 | Aug 19, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +2,777 | $18.36 | $51k | 2,777 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -70 | $107.11 | $7,498 | 2,707 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -737 | $108.17 | $80k | 1,970 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -831 | $108.95 | $91k | 1,139 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -272 | $109.96 | $30k | 867 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -470 | $111.05 | $52k | 397 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -397 | $111.77 | $44k | 0 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,777 | $0.00 | $0 | 22,223 | Aug 11, 2026 |
| May 21, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +6,090 | $0.00 | $0 | 6,090 | May 22, 2026 |
| May 22, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | May 22, 2025 |
Questions about Simon Read
Answered from the filings on this page, as of the latest one.
Is Simon Read buying or selling?
In the last 12 months Simon Read reported 0 open-market buys worth $0 and 2 open-market sells worth $631k on SEC Form 4; the latest was sold $327k of DNTH on Aug 19, 2026. Grants, option exercises and tax withholding are not counted.
How did Simon Read's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Simon Read has 0.
Where does Simon Read file Form 4?
Simon Read has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.